Thermo Fisher Scientific Inc. (TMO) fair value analysis
S&P 500 · Updated 2026-10-19
TMO price how computed
Forward Fair Value verdict
Fairly valuedTMO is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $658.02
- Sector
- Healthcare
- 12-month range
- $438.34–$696.49
- Market cap
- $243B
- From 52-week high
- -5.5%
- Shares outstanding
- 370M
- Rank in Healthcare by discount to fair value
- #57 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Thermo Fisher Scientific Inc. is a global life sciences company that provides laboratory equipment, reagents, consumables, and services to customers in research, clinical diagnostics, and bioproduction. The company operates across multiple continents and serves customers in pharmaceutical, biotechnology, academic, and healthcare organizations worldwide.
TMO currently ranks #57 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $243B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $46.3B
- Net margin
- 15.1%
- EPS (TTM)
- $23.83
- Gross margin
- 41.2%
- Debt / equity
- 0.81
- Revenue growth (3-yr avg)
- 4.5%
- Shares outstanding
- 370M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 61 · neutral
- 50-day average
- $636.69
- 200-day average
- $547.32
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $1.84 per share (4 payments)
- Yield on last price
- 0.28%
- Consecutive years of increases
- 8
- Last ex-dividend date
- 2026-09-15
- Last payment date
- 2026-10-15
Earnings how computed
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.6%)
2026-03 ▲ beat (+3.8%)
2025-12 ▲ beat (+1.9%)
2025-09 ▲ beat (+5.3%)
2025-06 ▲ beat (+2.5%)
2025-03 ▲ beat (+1.0%)
2024-12 ▲ beat (+2.7%)
2024-09 ▲ beat (+0.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 23 buy · 4 hold · 1 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $691
- Target vs last price
- +5.0%
What our data shows for TMO
- Our model validated 17 trailing price-to-earnings windows for TMO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $438.34–$696.49.
- The 14-day relative strength index sits at a neutral 61.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TMO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TMO news
TickrTrends' derived news-sentiment signal for TMO is currently leaning positive, computed from recent coverage.
- Thermo Fisher Scientific Inc (TMO) (Q3 2026) Earnings Call Highlights: Revenue Up 9% to $12.14 Billion, Adjusted EPS Jumps 15% and Full-Year Guidance Raised (gurufocus.com, 2026-10-21)
TickrTrends take: Thermo Fisher's third quarter results showed revenue growth of 9 percent alongside adjusted earnings per share growth of 15 percent, demonstrating operational leverage that outpaced top-line expansion. The company's decision to raise full-year guidance suggests management confidence in sustained momentum through the close of fiscal 2026. Given TickrTrends' assessment that TMO is fairly valued, investors should monitor whether this earnings beat and raised outlook narrow or widen any valuation gap relative to historical multiples in the Healthcare sector. - Tech Resilience and Earnings Anticipation Define Midweek Market Action (thestockmarketwatch.com, 2026-10-21)
TickrTrends take: TMO operates in the Healthcare sector and carries a TickrTrends valuation assessment of fairly valued. In a market environment where technology resilience and earnings anticipation are driving midweek activity, investors focused on valuation should monitor whether TMO's upcoming earnings reports validate or challenge its current fairly valued status. Given the company's position in healthcare and the broader market's earnings sensitivity, actual results could shift the valuation perspective if performance diverges from current market expectations. - Q3 2026 Thermo Fisher Scientific Inc Earnings Call Transcript (gurufocus.com, 2026-10-21)
TickrTrends take: Thermo Fisher Scientific's Q3 2026 earnings call provides an opportunity to assess whether the company's current financial performance supports its fairly valued designation within the Healthcare sector. Investors focused on valuation should monitor management commentary regarding revenue growth, margin expansion, and capital allocation decisions to determine if the company's fundamentals remain aligned with its current market pricing. Any material changes in guidance or business segment performance could signal whether the fairly valued assessment remains appropriate going forward.
More TMO news
- A Look at Thermo Fisher Scientific Inc (TMO) After 3.5% Gain -- GF Value $603.22 vs Price $696.49 (gurufocus.com, 2026-10-15)
- [Earnings]Semiconductor and Financial Leaders Drive Mid-October Earnings (thestockmarketwatch.com, 2026-10-14)
- PICTET ASSET MANAGEMENT SA Buys Elastic NV (ESTC) -- Shares Look 13% Undervalued on GF Value (gurufocus.com, 2026-10-13)
- TMO DCF Analysis: Intrinsic Value $421 vs Price $658 (gurufocus.com, 2026-10-12)
- Thermo Fisher Stock Trades at a Premium. Can Its Earnings Keep Up? (insidermonkey.com, 2026-10-11)
What people are saying
Follow the TMO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for TMO show that the company's quality grade improved from C to B this week. TMO remains in the Healthcare sector and maintains a valuation verdict of Fairly valued based on current analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for TMO show that the stock moved down in sector discount ranking this week, falling from position 63 to position 72 among Healthcare sector peers. The company remains assessed as fairly valued according to current valuation metrics.
- 2026-09-21 — TickrTrends' derived indicators for TMO show a shift in valuation assessment this week. The DCF cross-check band has moved from an overvalued designation to none, reflecting a change in the analytical framework applied to the Healthcare sector company. The current valuation verdict remains Fairly valued.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TMO stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), TMO is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is TMO's TickrTrends verdict?
TMO's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does TMO compare to other Healthcare stocks?
TMO ranks #57 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is TMO overbought or oversold?
TMO's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does TMO pay a dividend?
Yes. TMO paid $1.84 per share over the last twelve months (4 payments), a 0.28% yield on TickrTrends' last price, and has raised the annual total for 8 consecutive years. The last ex-dividend date was 2026-09-15.
Does TMO usually beat earnings estimates?
Over its last 8 reported quarters TMO beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TMO?
Of 28 analysts covering TMO, 23 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $691 (+5.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
TMO vs A · TMO vs ACHC · TMO vs AVAH · TMO vs COR · TMO vs CVS